Cargando…

HDACi Valproic Acid (VPA) and Suberoylanilide Hydroxamic Acid (SAHA) Delay but Fail to Protect against Warm Hepatic Ischemia-Reperfusion Injury

BACKGROUND: Histone deacetylases (HDAC) catalyze N-terminal deacetylation of lysine-residues on histones and multiple nuclear and cytoplasmic proteins. In various animal models, such as trauma/hemorrhagic shock, ischemic stroke or myocardial infarction, HDAC inhibitor (HDACi) application is cyto- an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruess, Dietrich A., Probst, Moriz, Marjanovic, Goran, Wittel, Uwe A., Hopt, Ulrich T., Keck, Tobias, Bausch, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981462/ https://www.ncbi.nlm.nih.gov/pubmed/27513861 http://dx.doi.org/10.1371/journal.pone.0161233

Ejemplares similares

Suberoylanilide Hydroxamic Acid (SAHA) Is a Driver Molecule of Neuroplasticity: Implication for Neurological Diseases
por: Verrillo, Lucia, et al.
Publicado: (2023)

In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
por: Tambunan, Usman SF, et al.
Publicado: (2011)

Effects of Suberoylanilide Hydroxamic Acid (SAHA) on the Inflammatory Response in Lipopolysaccharide-Induced N9 Microglial Cells
por: Çelik, Zülfinaz Betül, et al.
Publicado: (2022)

The Anti-Tumor Effects and Molecular Mechanisms of Suberoylanilide Hydroxamic Acid (SAHA) on the Aggressive Phenotypes of Ovarian Carcinoma Cells
por: Chen, Shuo, et al.
Publicado: (2013)

Suberoylanilide Hydroxamic Acid (SAHA) Treatment Reveals Crosstalk Among Proteome, Phosphoproteome, and Acetylome in Nasopharyngeal Carcinoma Cells
por: Huang, Huichao, et al.
Publicado: (2022)

The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Restores Cardiomyocyte Contractility in a Rat Model of Early Diabetes
por: Bocchi, Leonardo, et al.
Publicado: (2019)

Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms
por: Liu, Zhaohui, et al.
Publicado: (2014)

Transcriptional profiling of suberoylanilide hydroxamic acid (SAHA) regulated genes in mineralizing dental pulp cells at early and late time points
por: Duncan, Henry F., et al.
Publicado: (2015)

Suberoylanilide hydroxamic acid (SAHA) inhibits transforming growth factor-beta 2-induced increases in aqueous humor outflow resistance
por: Fujimoto, Tomokazu, et al.
Publicado: (2021)

Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog
por: Kumar, Bhavna, et al.
Publicado: (2015)

The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells
por: Lu, Hang, et al.
Publicado: (2016)

Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth
por: Said, Thenaa K, et al.
Publicado: (2001)

Suberoylanilide hydroxamic acid represses glioma stem-like cells
por: Hsu, Che-Chia, et al.
Publicado: (2016)

ING5‐mediated antineuroblastoma effects of suberoylanilide hydroxamic acid
por: Wu, Ji‐cheng, et al.
Publicado: (2018)

Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients
por: Sonnemann, Jürgen, et al.
Publicado: (2006)

Effects of Treatment with Suppressive Combination Antiretroviral Drug Therapy and the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid; (SAHA) on SIV-Infected Chinese Rhesus Macaques
por: Ling, Binhua, et al.
Publicado: (2014)

Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer
por: Tambunan, Usman Sumo Friend, et al.
Publicado: (2013)

Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway
por: Shi, Xuan-Yan, et al.
Publicado: (2017)

A Novel Osteogenic Activity of Suberoylanilide Hydroxamic Acid is Synergized by BMP-2
por: Lee, Zang Hee, et al.
Publicado: (2015)

The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Alleviates Salinity Stress in Cassava
por: Patanun, Onsaya, et al.
Publicado: (2017)

Epigenetic evidence of an Ac/Dc axis by VPA and SAHA
por: Lunke, Sebastian, et al.
Publicado: (2021)

Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma
por: Duvic, M, et al.
Publicado: (2006)

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
por: Min, Ahrum, et al.
Publicado: (2015)

Modulating Ocular Scarring in Glaucoma Filtration Surgery Using the Epigenetic Adjunct Suberoylanilide Hydroxamic Acid
por: Rodgers, Cooper D, et al.
Publicado: (2019)

In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi)
por: Friedrich, Annabelle, et al.
Publicado: (2020)

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006)

The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ
por: Klegeris, Andis, et al.
Publicado: (2012)

Chlorinated Polyketide Obtained from a Daldinia sp. Treated with the Epigenetic Modifier Suberoylanilide Hydroxamic Acid
por: Du, Lin, et al.
Publicado: (2014)

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, attenuates postoperative cognitive dysfunction in aging mice
por: Jia, Min, et al.
Publicado: (2015)

Suberoylanilide hydroxamic acid sensitizes neuroblastoma to paclitaxel by inhibiting thioredoxin‐related protein 14‐mediated autophagy
por: Zhen, Zijun, et al.
Publicado: (2017)

Suberoylanilide hydroxamic acid upregulates reticulophagy receptor expression and promotes cell death in hepatocellular carcinoma cells
por: Li, Jia-Yao, et al.
Publicado: (2023)

α,ß-Didehydrosuberoylanilide hydroxamic acid (DDSAHA) as precursor and possible analogue of the anticancer drug SAHA
por: Chattopadhyay, Shital K, et al.
Publicado: (2019)

Differential Gene Expression Profile Induced by Valproic Acid (VPA) in Pediatric Epileptic Patients
por: Floriano-Sánchez, Esaú, et al.
Publicado: (2018)

Exposure to valproic acid (VPA) reproduces hdac1 loss of function phenotypes in zebrafish
por: Jones, Alec A., et al.
Publicado: (2023)

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
por: Richon, V M
Publicado: (2006)

Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells
por: Sun, Pei-Chang, et al.
Publicado: (2010)

Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines
por: Oertel, Susanne, et al.
Publicado: (2011)

Cardiomyogenic Differentiation of Human Dental Follicle-derived Stem Cells by Suberoylanilide Hydroxamic Acid and Their In Vivo Homing Property
por: Sung, Iel-Yong, et al.
Publicado: (2016)

Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells
por: Zhang, Shirong, et al.
Publicado: (2016)

Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Enhances Radiosensitivity and Suppresses Lung Metastasis in Breast Cancer In Vitro and In Vivo
por: Chiu, Hui-Wen, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jktp7ipg38nrl4bv3n7206512h